摘要
目的:观察利拉鲁肽联合腹部闪罐治疗肥胖症的临床效果。方法:选取肥胖症患者119例,依据治疗方法不同分组,对照组59例予以利拉鲁肽注射液治疗。观察组60例在对照组基础上加用腹部闪罐治疗,分析比较两组患者肥胖度(A)、体脂百分率(F%)、身体质量指数(BMI)、体质量、血清空腹胰岛素(FINS)、空腹血糖(FBG)水平及不良反应。结果:治疗后观察组A、F%、BMI、体质量均显著低于对照组(P<0.01);经秩和检验可知,观察组临床效果显著优于对照组(P<0.01);观察组血清FINS、FPG水平显著低于对照组(P<0.01);观察组不良反应总发生率6.67%(4/60),与对照组3.39%(2/59)对比差异无统计学意义(P>0.05)。结论:利拉鲁肽联合腹部闪罐治疗肥胖症效果显著,可起到有效减肥作用,改善患者空腹胰岛素、血糖水平,且安全性较高。
Objective: To observe clinical effects of Liraglutide combined with abdominal flash capping in treatment of obesity.Methods: 119 patients with obesity were selected and divided into control group( n = 59) and observation group( n = 60) according to the different treatment methods. The control group was treated with Liraglutide,while the observation groupwas given Liraglutide combined with abdominal flash capping treatment. The obesity degree( A),body fat percentage( F%),body mass index( BMI),body mass index,serum fasting insulin( FINS) and fasting plasma glucose( FBG) levels were compared between the 2 groups before and after the treatment. The clinical effects and adverse reactions were compared between the 2 groups. Results: After the treatment,the A,F%,BMI and body weight of the observation group were significantly lower than those of the control group( P< 0.01). The rank sum test showed that the clinical effect of the observation group was better than that of the control group( P<0.01). After the treatment,the serum FINS and FPG levels in the observation group were significantly lower than those in the control group( P<0.01). The total incidence of adverse reactions in the observation group was 6.67%( 4/60); compared with 3.39% in the control group( 2/59),the difference was not statistically significant( P > 0. 05). Conclusions: Liraglutide combined with abdominal flashcupping for obesity patients has significant effects. It can effectively play a role in reducing weight and improving fasting insulin and blood sugar levels,and has a high safety.
出处
《中国民康医学》
2018年第2期75-77,共3页
Medical Journal of Chinese People’s Health